Corient Private Wealth
SPRY icon

Corient Private Wealth’s ARS Pharmaceuticals SPRY Stock Holding History

Corient Private Wealth’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$729K Buy
91,042
+10,099
+12% +$86.9K ﹤0.01% 1983
2026
Q1 		$650K Buy
+80,943
New +$776K ﹤0.01% 1889
2023
Q4 		– Sell
-10,042
Closed -$38K – 2344
2023
Q3 		$38K Buy
+10,042
New +$65.9K ﹤0.01% 2086

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Corient Private Wealth's SPRY Position: Q2 2026 in Review

Corient Private Wealth increased its ARS Pharmaceuticals (SPRY) stake by 12% in Q2 2026, buying an estimated $86.9K and bringing the position to 91,042 shares worth $729K. The position accounts for ﹤0.01% of the portfolio, ranked #1983.

Corient Private Wealth first reported a position in SPRY in Q3 2023 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Corient Private Wealth held 91,042 shares of ARS Pharmaceuticals worth $729K as of Q2 2026.
  • Corient Private Wealth bought 10,099 ARS Pharmaceuticals shares in Q2 2026, an estimated $86.9K.
  • ARS Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1983 holding.
  • Corient Private Wealth first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.